BlackRock, Inc. 13D and 13G filings for Revance Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-01-25 1:48 pm Purchase | 2023-12-31 | 13G | Revance Therapeutics, Inc. RVNC | BlackRock Inc. BLK | 7,453,371 8.500% | 380,690 (+5.38%) | Filing |
| 2023-02-03 4:27 pm Purchase | 2022-12-31 | 13G | Revance Therapeutics, Inc. RVNC | BlackRock Inc. BLK | 7,072,681 8.600% | 1,738,582 (+32.59%) | Filing |
| 2022-02-03 4:41 pm Purchase | 2021-12-31 | 13G | Revance Therapeutics, Inc. RVNC | BlackRock Inc. BLK | 5,334,099 7.400% | 321,747 (+6.42%) | Filing |
| 2021-02-05 07:51 am Purchase | 2020-12-31 | 13G | Revance Therapeutics, Inc. RVNC | BlackRock Inc. BLK | 5,012,352 7.500% | 1,323,695 (+35.89%) | Filing |